ORAL ABSTRACTS
Meritorious Abstract 1: Fifteen years of non-Hodgkin lymphoma in an Indonesian national referral hospital: Epidemiological trends and diagnostic challenges
Agnes Stephanie Harahap, 1,2 Maria Francisca Ham, 1,2 Andree Kurniawan, 3 Stefanny Charles, 2 Felix Wijovi, 2 Lugyanti Sukrisman4
1 Anatomical Pathology Department, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta 10430, Indonesia
2 Human Cancer Research Center-Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia
3 Subspecialist Program Study, Hematology and Medical Oncology, Internal Medicine Department, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta 10430, Indonesia
4 Hematology and Medical Oncology, Internal Medicine Department, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta 10430, Indonesia
Meritorious Abstract 2: Glofitamab in relapsed/refractory large B cell lymphoma: real-world experience
Ryan CW Ho, 1 Bonnie CS Kho, 1 Thomas SY Chan1
1Queen Mary Hospital, Hong Kong
Meritorious Abstract 3: Comparison of whole brain radiotherapy (WBRT) vs autologous transplantation (ASCT) in primary CNS lymphoma (PCNSL): a real world propensity score (PS) matching analysis
LM Poon, 1 Cherie Tan Jiao Jie, 1 Jayalakshmi, 1 Y Batumalai, 1 WT Ling, 1 S De Mel, 1 HL Chan, 1 WL Chan, 1 SX Lee, 1 YL Chee, 1 AD Jeyasekharan, 1 YS Chan, 2 N Somasundaram, 2 ST Lim, 2 WY Tan, 2 CK Ng, 2 LP Koh, 2 YH Tan2
1 National University Cancer Institute Singapore
2 National Cancer Center, Singapore
3 Singapore General Hospital
Meritorious Abstract 4: Barriers and Facilitators in B-Cell Non-Hodgkin Lymphoma Care: A Qualitative Study from the Philippines
Priscilla Caguioa, ¹ Junice Ng, ² Puja Khanna, ² Neeyor Bose, ³ Amanda Woo, ³ Yi Qi Ng, ³ Lalita Norasetthada⁴
¹ St. Luke’s Medical Center, Metro Manila, Philippines
² BeOne Medicines Ltd., Singapore
³ Oracle Life Sciences, Singapore
⁴ Chiang Mai University, Chiang Mai, Thailand
Meritorious Abstract 5: Outcomes of High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) in Relapsed/Refractory (RR) Diffuse Large B cell lymphoma (DLBCL): A 22-Year Single-Centre Experience from Singapore
Evelyn Aun Su-yin, 1 Esther Chan Hian Li, 1 Edwin Thong Wei Sheng, 1 Koh Liang Piu, 1 Tan Lip Kun, 1 Lim Hui Li, 1 Nur ‘Arifah Maziah Binte Moin, 1 Lee Foong Gwan, 1 Yelly Suhadi, 1 Belinda Tan, 1 Jedidiah Lieow, 1 Grace Chiam, 1 Victor Ling Wei Teik, 1 Poon Li Mei1
1 Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore
Special Encore Abstract 1: Five-Year Analysis of an Asia Subpopulation with Previously Untreated DLBCL Confirms Pola-R-CHP Benefit on Outcomes: The POLARIX Study
Yuqin Song 1 , Hervé Tilly 2 , Shinya Rai 3 , Huilai Zhang 4 , Jie Jin 5 , Hideki Goto 6 , Yoshiaki Ogawa 7 , Ho-Jin Shin 8 , Won Seog Kim 9 , Junning Cao 10 , Hyeon Seok Eom 11 , Dok Hyun Yoon 12 , Xavier Cheng-Hong Tsai 13 , Jyh-Pyng Gau 14 , Dai Maruyama 15 , Liling Zhang 16 , Yongping Song 17 , Yu Yang 18 , Wei Li 19 , He Huang 20 , Hiroshi Okamura 21 , Gilles Salles 22 , Laurie H. Sehn 23 , Lilian Bu 24 , Yanwen Jiang 25 , Saibah Chohan 26 , Matthew Sugidono 25 , Connie Lee Batlevi 25 , Mark Yan 26 , Claire Xu 24 , Stacey Huang 24 , Wenjin Li 27 , Ye Zhang 24 , Jun Zhu 1 , Koji Izutsu 28
1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China 2. Centre Henri Becquerel and University of Rouen, Rouen, France 3. Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka- Sayama, Japan 4. Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China 5. The First Affiliated Hospital of College of Medicine, Zhejiang University, Zhejiang, China 6. Department of Hematology, Hokkaido University Hospital, Sapporo, Japan 7. Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan 8. Pusan National University Hospital, Busan, Republic of Korea 9. Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea 10. Fudan University Shanghai Cancer Center, Shanghai, China 11. Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea 12. Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 13. National Taiwan University Hospital, Taipei, Taiwan 14. Taipei Veterans General Hospital, Taipei, Taiwan 15. Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan 16. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 17. Department of Hematology, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China 18. Department of Lymphoma, Head and Neck Oncology, Fujian Cancer Hospital, Fuzhou, China 19. Department of Hematology and Oncology, The First Hospital of Jilin University, Jilin, China 20. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China 21. Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan 22. Memorial Sloan Kettering Cancer Center, New York, USA 23. BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC, Canada 24. F. Hoffmann-La Roche Ltd, Shanghai, China 25. Genentech, Inc, South San Francisco, CA, USA 26. F. Hoffmann-La Roche Ltd, Mississauga, Canada 27. Roche (China) Holding Ltd, Shanghai, China 28. National Cancer Center Hospital, Tokyo, Japan
Special Encore Abstract 2: Mosunetuzumab plus polatuzumab vedotin is superior to R-GemOx in transplant-ineligible patients with R/R LBCL: primary results of the Phase III SUNMO trial
Wonseog Kim1, Jason Westin2, Huilai Zhang3, Laura Maria Fogliatto4, Dai Maruyama5, Eduardo M Redo6, Danielle Leão Cordeiro de Farias7, Lalita Norasetthada8, Huangming Hong9, Muhit Ozcan10, Young-Woo Jeon11, Astrid Pavlovsky12, Hideki Goto13, Adam Olszewski14, Nikesh Shah15, Bei Hu16, Shen Yin17, Martin Janousek18, Jue Wang17, Connie Lee Batlevi17, Michael C. Wei17, L. Elizabeth Budde19
1 Samsung Medical Center, Seoul, South Korea
2 MD Anderson Cancer Center, Houston, TX, USA
3 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
4 Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
5 Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
6 Instituto D’Or de Pesquisa e Ensino, Sao Paulo, Brazil
7 Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil
8 Faculty of Medicine, Chiang Mai University, Thailand
9 Si Chuan Cancer Hospital, Chengdu, China
10 Ankara University School of Medicine, Ankara, Turkey
11 Yeouido St. Mary’s Hospital, Seoul, South Korea
12 Fundaleu, Buenos Aires, Argentina
13 Department of Hematology, Hokkaido University Hospital, Sapporo, Japan
14 Brown University, Providence, RI, USA’
15 Tampa General Hospital Cancer Institute, Tampa, FL, USA
16 Atrium Health Levine Cancer Institute and Wake Forest School of Medicine, Charlotte, NC, USA
17 Genentech, Inc., South San Francisco, CA, USA
18 F. Hoffmann-La Roche Ltd, Basel, Switzerland
19 City of Hope National Medical Center, Duarte, CA, USA
POSTER ABSTRACTS
Poster 1. Clinicopathologic Characteristics and Event Free Survival of Diffuse Large B-Cell Lymphoma Patients in Indonesia
Nia Novianti Siregar, 1 Cosphiadi Irawan, 2 Maria Francisca Ham, 3 Ikhwan Rinaldi2
1 Department of Hematology and Medical Oncology, Dharmais National Cancer Centre Hospital, Jakarta, Indonesia
2 Hematology and Medical Oncology Division, Internal Medicine Department, Faculty of Medicine University of Indonesia – Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
3 Department of Anatomical Pathology, Faculty of Medicine University of Indonesia – Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
Poster 2. Lung Fibrosis in Lymphoma Patients: case series and literature review
Amaylia Oehadian, 1 Melati Hidayanti, 2 Iceu Dimas Kulsum, 3 Emmy Hermiyanti Pranggono, 3 Dewi Kartika Turbawaty4
1 Hematology and Medical Oncology Division, Department of Internal Medicine, Hasan Sadikin Hospital, Padjadjaran University, Bandung, Indonesia
2 Department of Internal Medicine, Hasan Sadikin Hospital, Padjadjaran University, Bandung, Indonesia
3 Pulmonology and Medic Critic Division, Department of Internal Medicine, Hasan Sadikin Hospital, Padjadjaran University, Bandung, Indonesia
4 Department of Clinical Pathology, Hasan Sadikin Hospital, Padjadjaran University, Bandung, Indonesia
Poster 3. EXPLORING THE PSYCHOSOCIAL NEEDS OF WORKING-AGE MALE BLOOD CANCER PATIENTS THROUGH A PATIENT JOURNEY MAP (QUALITATIVE STUDY)
Candice Chiew, 1 Bi Yu Yap1
1 Leukemia and Lymphoma Foundation
Poster 4. Clinical patterns and prognostic outcomes of Asian ocular adnexal marginal zone lymphoma
Rowena Lee Ying Kwan, 1, 2 Ryan Mao Heng Lim, 2 Jason Yongsheng Chan 2, 3, 4
1 Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
3 SingHealth Duke-NUS Blood Cancer Centre, Singapore
4 Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore
Poster 5. FrenchConnect & CESAR Project: Real-life ctDNA-based Monitoring in Mantle Cell Lymphoma
Yannick Le Bris1
1Nantes University Hospital & CALYM
Poster 6. Overcoming Treatment Challenges with Glofitamab Following BTK Inhibitor Failure: A Case Report of an Elderly Patient with Rapidly Progressing Relapsed MCL
Yuen-Ting SIN, 1 Chung-Yin HA1
1 Division of Haematology, Department of Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong
Poster 7. Old is gold
Kavuru Naga Siri, M Manickavasagam, A Ravichandran
Poster 8. Clinical Portrait of Classical Hodgkin Lymphoma in Indonesia: Insights from ABVD-Treated Patients at a National Referral Center
Devi A. R. Amelia, 1 Anna M. Lubis, 2 Agnes S. Harahap, 3 Sukamto Koesnoe, 4 Andree Kurniawan, 1,5 Chandra Sari, 1 Deden Djatnika, 1 Dimas Priantono, 1 Nugraheni P. Purlikasari, 1 Beta A. Wisman, 1 Farieda Ariyanti1
1 Fellow in Hematology and Medical Oncology, Faculty of Medicine Universitas Indonesia – RS Cipto Mangunkusumo, Jakarta, Indonesia
2 Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – RS Cipto Mangunkusumo, Jakarta, Indonesia
3 Department of Anatomical Pathology, Faculty of Medicine Universitas Indonesia – RS Cipto Mangunkusumo, Jakarta, Indonesia
4 Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – RS Cipto Mangunkusumo, Jakarta, Indonesia
5 Departemen of Internal Medicine, Faculty of Medicine Universitas Tarumanegara, Tangerang, Indonesia
Poster 9. Hodgkin Lymphoma Presenting with Multiple Life-Threatening Emergencies: A Case Report
Chandra Sari1
1 Fellow in hematology and medical oncology, University of Indonesia
Poster 10. Prognostic factors and outcome in patients with late relapse diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation
Jing Yuan Tan1
1 Department of Haematology, Singapore General Hospital, Singapore
Poster 11. Immune-Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Pediatric Patients Receiving CAR T-Cell Therapy: A Scoping Review
Laura Jane Koh, 1 Tan Ya Hwee, 1 Sophia Wong Yien Ning, 1 Evelyn Yi Ting Wong1
1 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
Poster 12. Cancer Screening Practices for Secondary Solid Malignancies After Hematopoietic Stem Cell Transplantation: A Scoping Review
Caitlyn Png Shu Yi, 1 Tan Ya Hwee, 1 Evelyn Yi Ting Wong1
1 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
Poster 13. Familial Simulataneus Co-occurrence of Classical Hodgkin and Diffuse Large B-Cell Lymphoma: A Case Report of a Father and Son with Divergent Clinical Courses
Shafira Puspadina
Poster 14. Systematic Literature Review and Meta-analysis of Chimeric antigen receptor T cell therapy (CAR T) vs Bispecific Antibody Therapy as Third or Later-line Follicular Lymphoma Treatment
Lawrence CK Ng, 1 Yan Chin Tan, 1 Xiu Hue Lee, 1 Miny Samuel, 2 Michelle LM Poon2
1 Department of Haematology, Singapore General Hospital, Singapore2 Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, Singapore
Poster 15. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory
(R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO
Chieh-Lin Jerry Teng, 1 Jeremy S. Abramson, 2 Matthew Ku, 3 Mark Hertzberg, 4 Christopher P. Fox, 5 Charles Herbaux, 6 Hui-Qiang Huang, 7 Dok Hyun Yoon, 8 Won Seog Kim, 9 Huilai Zhang, 10 Haifaa Abdulhaq, 11 William Townsend, 12 Estefania Mulvihill, 13 Victor Orellana-Noia, 14 Richard Ta, 14 Huang Huang, 15 Martine Joanna Kallemeijn, 13 Anton Belousov, 13 Alessia Bottos, 13 Linda Lundberg, 13 Gareth P. Gregory 16
1 Taichung Veterans General Hospital, Taichung
2 Massachusetts General Hospital Cancer Center, Boston, MA, USA
3 St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
4 Prince of Wales Hospital and UNSW, Department of Haematology, Sydney, Australia
5 School of Medicine, University of Nottingham, UK
6 University Hospital of Montpellier, Montpellier, France
7 Sun Yat-sen University Cancer Center, Guangzhou, China
8 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
9 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
10 Tianjin Medical University Cancer Institute, Tianjin, China
11 University of California San Francisco, Fresno Campus, CA, USA
12 University College London Hospitals, London, UK
13 F. Hoffmann-La Roche Ltd, Basel, Switzerland
14 Genentech, Inc., South San Francisco, CA, USA
15 F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada
16 School of Clinical Sciences at Monash Health, Monash University, Melbourne, and Fiona Stanley Hospital, Perth, Australia
Poster 16. A Multinational Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma (ENKL)
Jason Yongsheng Chan,1 Koji Izutsu,2 Motoko Yamaguchi,3 Dai Maruyama,4 Tatsu Shimoyama,5 Keisuke Seike,6 Hiroshi Arima,7 Noriko Fukuhara,8 Shigeru Kusumoto,9 Kohji Shimasaki,10 Koji Fukushima,10 and Kensei Tobinai2
1 National Cancer Centre Singapore, Singapore
2 National Cancer Center Hospital, Tokyo, Japan
3 Mie University Hospital, Tsu, Japan
4 Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
5 Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
6 Okayama University Hospital, Okayama, Japan
7 Kyoto University Hospital, Kyoto, Japan
8 Tohoku University Hospital, Sendai, Japan
9 Aichi Cancer Center, Nagoya, Japan
10 SymBio Pharmaceuticals Limited, Tokyo, Japan
Poster 17. Clinicopathological Analysis of Therapeutic Response in Non-GCB DLBCL: A Retrospective Study in Hasan Sadikin General Hospital, Bandung
Arnita Ilanur,1 Bethy S. Hernowo,1 Hasrayati Agustina,1 Amaylia Oehadian2
1 Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran/ Dr. Hasan Sadikin General Hospital Bandung
2 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/ Dr. Hasan Sadikin General Hospital Bandung